Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.
Hepatitis C (HCV) disproportionately affects people who inject drugs (PWID). Despite availability of safe and effective treatment, HCV treatment access and uptake among PWID in low- and middle-income countries (LMICs) has been limited. Understanding the lived experiences of PWID in these settings wh...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLOS Global Public Health |
| Online Access: | https://doi.org/10.1371/journal.pgph.0003284 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832539997234790400 |
|---|---|
| author | Hannah N Manley Lindsey R Riback Mercy Nyakowa Matthew J Akiyama Peter Cherutich John Lizcano Ann Kurth Abbe Muller |
| author_facet | Hannah N Manley Lindsey R Riback Mercy Nyakowa Matthew J Akiyama Peter Cherutich John Lizcano Ann Kurth Abbe Muller |
| author_sort | Hannah N Manley |
| collection | DOAJ |
| description | Hepatitis C (HCV) disproportionately affects people who inject drugs (PWID). Despite availability of safe and effective treatment, HCV treatment access and uptake among PWID in low- and middle-income countries (LMICs) has been limited. Understanding the lived experiences of PWID in these settings who have undergone treatment provides the opportunity to gain insight into how to implement treatment programs that meet the needs of this population. Using Rhodes' Risk Environment Framework to guide our work, we conducted semi-structured interviews with 35 PWID who received HCV treatment in methadone clinics and drop-in-centers (DICs) in Nairobi and coastal Kenya supported by peer case managers from August to September 2019. Translated and transcribed interviews were analyzed thematically. Three overarching themes emerged in our thematic analysis: 1) Financial constraints as a barrier to HCV treatment, 2) HCV-related stigma, and 3) HCV treatment impacts on health and risk behaviors. These data signal unique challenges faced by PWID seeking HCV treatment in this LMIC setting and highlight the importance of interventions to reduce barriers to treatment. In order for positive treatment outcomes to be sustained, HCV treatment programs must address the barriers patients face at multiple levels and implement system-level changes. |
| format | Article |
| id | doaj-art-d231172f75894623801ff3849ce2bb1d |
| institution | Kabale University |
| issn | 2767-3375 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLOS Global Public Health |
| spelling | doaj-art-d231172f75894623801ff3849ce2bb1d2025-02-05T05:50:26ZengPublic Library of Science (PLoS)PLOS Global Public Health2767-33752025-01-0151e000328410.1371/journal.pgph.0003284Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.Hannah N ManleyLindsey R RibackMercy NyakowaMatthew J AkiyamaPeter CherutichJohn LizcanoAnn KurthAbbe MullerHepatitis C (HCV) disproportionately affects people who inject drugs (PWID). Despite availability of safe and effective treatment, HCV treatment access and uptake among PWID in low- and middle-income countries (LMICs) has been limited. Understanding the lived experiences of PWID in these settings who have undergone treatment provides the opportunity to gain insight into how to implement treatment programs that meet the needs of this population. Using Rhodes' Risk Environment Framework to guide our work, we conducted semi-structured interviews with 35 PWID who received HCV treatment in methadone clinics and drop-in-centers (DICs) in Nairobi and coastal Kenya supported by peer case managers from August to September 2019. Translated and transcribed interviews were analyzed thematically. Three overarching themes emerged in our thematic analysis: 1) Financial constraints as a barrier to HCV treatment, 2) HCV-related stigma, and 3) HCV treatment impacts on health and risk behaviors. These data signal unique challenges faced by PWID seeking HCV treatment in this LMIC setting and highlight the importance of interventions to reduce barriers to treatment. In order for positive treatment outcomes to be sustained, HCV treatment programs must address the barriers patients face at multiple levels and implement system-level changes.https://doi.org/10.1371/journal.pgph.0003284 |
| spellingShingle | Hannah N Manley Lindsey R Riback Mercy Nyakowa Matthew J Akiyama Peter Cherutich John Lizcano Ann Kurth Abbe Muller Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study. PLOS Global Public Health |
| title | Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study. |
| title_full | Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study. |
| title_fullStr | Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study. |
| title_full_unstemmed | Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study. |
| title_short | Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study. |
| title_sort | barriers to and impacts of hepatitis c treatment among people who inject drugs in kenya a qualitative study |
| url | https://doi.org/10.1371/journal.pgph.0003284 |
| work_keys_str_mv | AT hannahnmanley barrierstoandimpactsofhepatitisctreatmentamongpeoplewhoinjectdrugsinkenyaaqualitativestudy AT lindseyrriback barrierstoandimpactsofhepatitisctreatmentamongpeoplewhoinjectdrugsinkenyaaqualitativestudy AT mercynyakowa barrierstoandimpactsofhepatitisctreatmentamongpeoplewhoinjectdrugsinkenyaaqualitativestudy AT matthewjakiyama barrierstoandimpactsofhepatitisctreatmentamongpeoplewhoinjectdrugsinkenyaaqualitativestudy AT petercherutich barrierstoandimpactsofhepatitisctreatmentamongpeoplewhoinjectdrugsinkenyaaqualitativestudy AT johnlizcano barrierstoandimpactsofhepatitisctreatmentamongpeoplewhoinjectdrugsinkenyaaqualitativestudy AT annkurth barrierstoandimpactsofhepatitisctreatmentamongpeoplewhoinjectdrugsinkenyaaqualitativestudy AT abbemuller barrierstoandimpactsofhepatitisctreatmentamongpeoplewhoinjectdrugsinkenyaaqualitativestudy |